Drug Search Results
More Filters [+]

DTA-H19

Alternative Names: dta-h19, dtah19, dta h19
Latest Update: 2019-11-01
Latest Update Note: Clinical Trial Update

Product Description

A plasmid DNA encoding the A chain of the diphtheria toxin (DT-A) driven by the transcriptional regulatory sequences of human H19, with potential antineoplastic activity. Because the expression of DT-A is under the control of H19 promotor elements, DT-A is selectively expressed in tumor cells capable of turning on H-19.

Mechanisms of Action: ADPr Catalyzer

Novel Mechanism: Yes

Modality: Gene Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ChemomAb
Company Location: TEL AVIV L3 6158002
Company CEO: Dale Pfost
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for DTA-H19

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Pancreatic Cancer|Ovarian Cancer|Bladder Cancer|Diphtheria|Carcinoma in Situ|Transitional Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BC-07-01.CTIL

P2

Completed

Bladder Cancer

2013-01-01

BC-08-01

P2

Completed

Ovarian Cancer

2012-02-01

BC-07-05

P2

Completed

Pancreatic Cancer

2010-10-01

BC-05-02.CTIL

P2

Completed

Bladder Cancer|Transitional Cell Carcinoma|Carcinoma in Situ|Diphtheria

2007-11-01

Recent News Events

Date

Type

Title